Email updates

Keep up to date with the latest news and content from Epigenetics & Chromatin and BioMed Central.

This article is part of the supplement: Epigenetics and Chromatin: Interactions and processes

Open Access Poster presentation

MeCP2 binds to 5hmc enriched within active genes and accessible chromatin in the nervous system

Marian Mellen1*, Pinar Ayata1, Scott Dewell2, Skirmantas Kriaucionis3 and Nathaniel Heintz1

  • * Corresponding author: Marian Mellen

  • † Equal contributors

Author Affiliations

1 Laboratory of Molecular Biology, Howard Hughes Medical Institute, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA

2 Genomics Resource Center, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA

3 Laboratory of Epigenetic Mechanisms, Ludwig Institute for Cancer Research, The University of Oxford, ORCRB, Oxford, OX37DQ, UK

For all author emails, please log on.

Epigenetics & Chromatin 2013, 6(Suppl 1):P52  doi:10.1186/1756-8935-6-S1-P52

The electronic version of this article is the complete one and can be found online at:

Published:18 March 2013

© 2013 Mellen et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Poster presentation

The very high levels of 5-hydroxymethylcytosine (5hmC) present in neuronal genomes and its accumulation within gene bodies suggests that the epigenetic mechanisms interpreting 5hmC in the central nervous system (CNS) may differ from those present in embryonic stem (ES) cells. Here we present the first quantitative, genome-wide analysis of 5hmC, 5-methylcytosine (5mC) and gene expression in identified, terminally differentiated CNS cell types in vivo. We report that the high level of 5hmC present in neurons is enriched in active transcription units, and that surprisingly strong depletion of 5mC over gene bodies is observed for these genes. However, the relative contribution of these epigenetic marks to gene expression depends critically on cell type. We identify methyl-CpG binding protein 2 (MeCP2) as the major 5hmC binding protein in the brain, and demonstrate that MeCP2 binds 5hmC and 5mC containing DNA with similar high affinities. The Rett Syndrome causing mutation of residue R133C in the MeCP2 methyl-CpG binding domain (MBD) preferentially inhibit 5hmC binding. Loss of MeCP2 does not alter the genomic distribution of 5hmC. These findings demonstrate that 5hmC and MeCP2 constitute a novel, cell specific epigenetic mechanism for regulation of chromatin structure and gene expression in the mammalian nervous system, and they provide new mechanistic insights into the pathophysiology of Rett Syndrome (RTT).